CMS recently launched the Medicare GLP-1 Bridge, a short-term demonstration that provides eligible Part D beneficiaries with access to certain glucagon‐like peptide‐1 (GLP-1) drugs for $50 per month.
Denials are exposing operational weaknesses that extend far beyond reimbursement, and hospitals can no longer afford to treat them as an unavoidable cost of doing business.
